Magnesium sulphate at 30 to 34 weeks’ gestational age: neuroprotection trial (MAGENTA) - study protocol

[1]  Craig A. Albers,et al.  Third Edition. San Antonio, TX: Harcourt Assessment - Test Review: Bayley, N. (2006). Bayley Scales of Infant and Toddler Development , 2014 .

[2]  Nancy Bayley,et al.  BAYLEY SCALES OF INFANT AND TODDLER DEVELOPMENT, THIRD EDITION (BAYLEY-III) , 2014 .

[3]  S. PaulaSperry,et al.  Effect of magnesium sulfate given for neuroprotection before pretermbirth: a randomized controlled trial , 2011 .

[4]  I. Novak,et al.  Consensus research priorities for cerebral palsy: a Delphi survey of consumers, researchers, and clinicians , 2010, Developmental medicine and child neurology.

[5]  N. Mcdonnell.  Cardiopulmonary arrest in pregnancy: two case reports of successful outcomes in association with perimortem Caesarean delivery. , 2009, British journal of anaesthesia.

[6]  Gabriel J Escobar,et al.  Increased risk of adverse neurological development for late preterm infants. , 2009, The Journal of pediatrics.

[7]  Neil Marlow,et al.  The Cost of Preterm Birth Throughout Childhood in England and Wales , 2009, Pediatrics.

[8]  Z. Bhutta,et al.  BMC Pregnancy and Childbirth , 2009 .

[9]  N. Paneth.  Establishing the diagnosis of cerebral palsy. , 2008, Clinical obstetrics and gynecology.

[10]  F. Malone,et al.  A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. , 2008, The New England journal of medicine.

[11]  Saroj Saigal,et al.  An overview of mortality and sequelae of preterm birth from infancy to adulthood , 2008, The Lancet.

[12]  S. Marret,et al.  Benefit of Magnesium Sulfate Given Before Very Preterm Birth to Protect Infant Brain , 2008, Pediatrics.

[13]  J. Dungan.  Outcomes at 2 Years of Age After Repeat Doses of Antenatal Corticosteroids , 2008 .

[14]  L. Doyle,et al.  Outcomes at 2 years of age after repeat doses of antenatal corticosteroids. , 2007, The New England journal of medicine.

[15]  M. Kaminski,et al.  Neonatal and 5-Year Outcomes After Birth at 30–34 Weeks of Gestation , 2007, Obstetrics and gynecology.

[16]  E. Sullivan,et al.  Australia's mothers and babies 2007 , 2008 .

[17]  L. Doyle.  Changing availability of neonatal intensive care for extremely low birthweight infants in Victoria over two decades , 2004, The Medical journal of Australia.

[18]  B. Rosner,et al.  Blood pressure nomograms for children and adolescents, by height, sex, and age, in the United States , 1993, Pediatric Nephrology.

[19]  Babak Shahian Jahromi,et al.  Magnesium and experimental vasospasm. , 2004, Journal of neurosurgery.

[20]  L. Doyle,et al.  Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. , 2003, JAMA.

[21]  S. Starkman,et al.  Potential role of neuroprotective agents in the treatment of patients with acute ischemic stroke , 2003, Current treatment options in neurology.

[22]  A. Miyamoto,et al.  Enhanced release of IL‐1β and TNF‐α following endotoxin challenge from rat alveolar macrophages cultured in low‐Mg 2+ medium , 2003 .

[23]  D. Henderson-smart,et al.  Magnesium sulphate and other anticonvulsants for women with pre-eclampsia. , 2003, The Cochrane database of systematic reviews.

[24]  T. McElrath.  Association between use of antenatal magnesium sulfate in preterm labor and adverse health outcomes in infants. , 2003, American journal of obstetrics and gynecology.

[25]  A. Miyamoto,et al.  Enhanced release of IL-1beta and TNF-alpha following endotoxin challenge from rat alveolar macrophages cultured in low-mg(2+) medium. , 2003, Magnesium research.

[26]  M. Yeargin-Allsopp,et al.  Trends in the prevalence of cerebral palsy in a population-based study. , 2002, Pediatrics.

[27]  A. Colver,et al.  Analysis by gestational age of cerebral palsy in singleton births in north-east England 1970-94. , 2002, Paediatric and perinatal epidemiology.

[28]  U. Ekblad,et al.  Comparison of the effects of antenatal magnesium sulphate and ritodrine exposure on circulatory adaptation in preterm infants , 2002, Clinical physiology and functional imaging.

[29]  L. Doyle,et al.  Magnesium sulphate for preventing preterm birth in threatened preterm labour. , 2002, The Cochrane database of systematic reviews.

[30]  A. Lusky,et al.  Effect of maternal tocolysis on the incidence of severe periventricular/intraventricular haemorrhage in very low birthweight infants , 2001, Archives of disease in childhood. Fetal and neonatal edition.

[31]  K. Nelson,et al.  Magnesium sulfate for tocolysis and risk of spastic cerebral palsy in premature children born to women without preeclampsia. , 2000, American journal of obstetrics and gynecology.

[32]  A. Gülmezoglu,et al.  Anticonvulsants for women with pre-eclampsia. , 2000, The Cochrane database of systematic reviews.

[33]  G. Thurnau,et al.  The Effect of Maternal Magnesium Sulfate Treatment on Neonatal Morbidity in ≤1000-gram Infants , 1999 .

[34]  D. Strauss,et al.  Life expectancy of children with cerebral palsy. , 1998, Pediatric neurology.

[35]  K. Leveno.  Tocolytic magnesium sulphate and paediatric mortality , 1998, The Lancet.

[36]  J. Carlin,et al.  Tocolytic magnesium sulphate and paediatric mortality , 1998, The Lancet.

[37]  T. O'Shea,et al.  Intrauterine infection and the risk of cerebral palsy in very low-birthweight infants. , 1998, Paediatric and perinatal epidemiology.

[38]  S. Selvin,et al.  Magnesium sulfate tocolysis and risk of neonatal death. , 1998, American journal of obstetrics and gynecology.

[39]  G. Thurnau,et al.  The effect of maternal magnesium sulfate treatment on neonatal morbidity in < or = 1000-gram infants. , 1998, American journal of perinatology.

[40]  C. Shen,et al.  Effect of magnesium sulfate on the development of cystic periventricular leukomalacia in preterm infants. , 1997, American journal of perinatology.

[41]  J. Pinto-Martin,et al.  Magnesium sulfate in labor and risk of neonatal brain lesions and cerebral palsy in low birth weight infants. The Neonatal Brain Hemorrhage Study Analysis Group. , 1997, Pediatrics.

[42]  R. Palisano,et al.  Development and reliability of a system to classify gross motor function in children with cerebral palsy , 1997, Developmental medicine and child neurology.

[43]  C. Berg,et al.  Prenatal magnesium sulfate exposure and the risk for cerebral palsy or mental retardation among very low-birth-weight children aged 3 to 5 years. , 1997, JAMA.

[44]  L. Graziani,et al.  MATERNALLY-ADMINISTERED MAGNESIUM SULFATE (MgSO4) PROTECTS AGAINST EARLY BRAIN INJURY AND LONG-TERM ADVERSE NEURODEVELOPMENTAL OUTCOMES IN PRETERM INFANTS: A PROSPECTIVE STUDY. 1502 , 1996, Pediatric Research.

[45]  V. Fellman,et al.  Acute effects of two different doses of magnesium sulphate in infants with birth asphyxia. , 1995, Archives of disease in childhood. Fetal and neonatal edition.

[46]  T J Cole,et al.  Cross sectional stature and weight reference curves for the UK, 1990. , 1995, Archives of disease in childhood.

[47]  K. Nelson,et al.  Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? , 1995, Pediatrics.

[48]  R. Ehrenkranz,et al.  Recombinant human erythropoietin stimulates erythropoiesis and reduces erythrocyte transfusions in very low birth weight preterm infants. , 1995, Pediatrics.

[49]  Australia's mothers and babies. , 1995, Australian health review : a publication of the Australian Hospital Association.

[50]  M. Delivoria-Papadopoulos,et al.  Protective effect of MgSO4 infusion on NMDA receptor binding characteristics during cerebral cortical hypoxia in the newborn piglet , 1994, Brain Research.

[51]  E. Shalev,et al.  The combination of magnesium sulphate and nifedipine: a cause of neuromuscular blockade , 1994, British journal of obstetrics and gynaecology.

[52]  M. Hallak,et al.  Transfer of maternally administered magnesium sulfate into the fetal compartment of the rat: assessment of amniotic fluid, blood, and brain concentrations. , 1993, American journal of obstetrics and gynecology.

[53]  F. Stanley,et al.  Trends in perinatal mortality and cerebral palsy in Western Australia, 1967 to 1985. , 1992, BMJ.

[54]  M. Cardwell,et al.  Neuromuscular blockade with magnesium sulfate and nifedipine. , 1990, American journal of obstetrics and gynecology.

[55]  R. Vink,et al.  Magnesium protects against neurological deficit after brain injury , 1989, Brain Research.

[56]  A. Baraka,et al.  Neuromuscular interaction of magnesium with succinylcholine-vecuronium sequence in the eclamptic parturient. , 1987, Anesthesiology.

[57]  A. Mildvan.  Role of magnesium and other divalent cations in ATP-utilizing enzymes. , 1987, Magnesium.

[58]  L. Nowak,et al.  Magnesium gates glutamate-activated channels in mouse central neurones , 1984, Nature.

[59]  P. Lipsitz.  The clinical and biochemical effects of excess magnesium in the newborn. , 1971, Pediatrics.